Table 2. Patient summary UPN . Dose... | American Society of Hematology

Table 2.

Patient summary

UPN	Dose level (mCi/kg)	Age at AHCT, y	Prior lines	Diagnosis	Prior therapies	Disease status at AHCT	Response after AHCT, day 100	Current status
1	0.4	50	1	PTCL-NOS	R-EPOCH ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
2	0.4	45	1	PTCL-NOS	R-EPOCH ×6	CR1	CR	Relapsed at day +301, died of PTCL ∼17 mos after AHCT
4	0.4	50	1	AITL	CHOEP ×6	CR1	CR	Alive without relapse ∼1.5 y after AHCT
5	0.4	71	1	PTCL-NOS	CHOP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
6	0.5	48	1	HSTCL	EPOCH + BV ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
7	0.5	74	1	MEITL	CHOEP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
9	0.5	76	1	PTCL-NOS	CHOEP ×6	CR1	CR	Relapsed at day +218, died of PTCL ∼11 mos after AHCT
10	0.5	18	1	PTCL-NOS	CHOEP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
11	0.6	41	2	PTCL-NOS	CHOP ×6	CR1	CR	Relapsed at day +514, still alive ∼2 y after AHCT
12	0.6	51	1	ALK-ve ALCL	CHOEP ×6	CR1	CR	Alive without relapse ∼1 y after AHCT
13	0.6	60	1	AITL	CHOEP ×6	CR1	Relapse	Relapsed at day +108, died of PTCL ∼21 mos after AHCT
14	0.6	52	1	ALK-ve ALCL	CHOP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
15	0.6	44	2	ALK-ve ALCL	ABVD – BV ×6 (CR1)	CR2	Relapse	Relapsed at day +105, died of PTCL ∼9 mos after AHCT
16	0.6	76	2	MEITL	Newcastle regimen (CR1) Gem/Ox – CR2	CR2	Relapse	Relapsed at day +118, died of PTCL ∼18 mos after AHCT
17	0.6	54	1	AITL	CHOEP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
18	0.6	62	1	PTCL-NOS	CHOP ×6	CR1	CR	Relapsed at day +269, died of multiorgan failure ∼9 mos after AHCT
19	0.6	62	1	PTCL-NOS	CHOP ×6	CR1	CR	Relapsed at day +360, still alive ∼2 y after AHCT
20	0.6	63	4	PTCL-NOS CD30⁺	Cytoxan ×1, etoposide ×1, romidepsin ×3 infusions, BV ×6 – CR1	CR1	CR	Alive without relapse ∼1.5 y after AHCT
21	0.6	46	2	ALK-ve ALCL	CHOEP ×3 – BV ×8 – CR1	CR1	CR	Alive without relapse ∼1.5 y after AHCT
22	0.6	32	1	ALK-ve ALCL	A + CHP ×6	CR1	CR	Alive without relapse ∼7 mos after AHCT

UPN	Dose level (mCi/kg)	Age at AHCT, y	Prior lines	Diagnosis	Prior therapies	Disease status at AHCT	Response after AHCT, day 100	Current status
1	0.4	50	1	PTCL-NOS	R-EPOCH ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
2	0.4	45	1	PTCL-NOS	R-EPOCH ×6	CR1	CR	Relapsed at day +301, died of PTCL ∼17 mos after AHCT
4	0.4	50	1	AITL	CHOEP ×6	CR1	CR	Alive without relapse ∼1.5 y after AHCT
5	0.4	71	1	PTCL-NOS	CHOP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
6	0.5	48	1	HSTCL	EPOCH + BV ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
7	0.5	74	1	MEITL	CHOEP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
9	0.5	76	1	PTCL-NOS	CHOEP ×6	CR1	CR	Relapsed at day +218, died of PTCL ∼11 mos after AHCT
10	0.5	18	1	PTCL-NOS	CHOEP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
11	0.6	41	2	PTCL-NOS	CHOP ×6	CR1	CR	Relapsed at day +514, still alive ∼2 y after AHCT
12	0.6	51	1	ALK-ve ALCL	CHOEP ×6	CR1	CR	Alive without relapse ∼1 y after AHCT
13	0.6	60	1	AITL	CHOEP ×6	CR1	Relapse	Relapsed at day +108, died of PTCL ∼21 mos after AHCT
14	0.6	52	1	ALK-ve ALCL	CHOP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
15	0.6	44	2	ALK-ve ALCL	ABVD – BV ×6 (CR1)	CR2	Relapse	Relapsed at day +105, died of PTCL ∼9 mos after AHCT
16	0.6	76	2	MEITL	Newcastle regimen (CR1) Gem/Ox – CR2	CR2	Relapse	Relapsed at day +118, died of PTCL ∼18 mos after AHCT
17	0.6	54	1	AITL	CHOEP ×6	CR1	CR	Alive without relapse ∼2 y after AHCT
18	0.6	62	1	PTCL-NOS	CHOP ×6	CR1	CR	Relapsed at day +269, died of multiorgan failure ∼9 mos after AHCT
19	0.6	62	1	PTCL-NOS	CHOP ×6	CR1	CR	Relapsed at day +360, still alive ∼2 y after AHCT
20	0.6	63	4	PTCL-NOS CD30⁺	Cytoxan ×1, etoposide ×1, romidepsin ×3 infusions, BV ×6 – CR1	CR1	CR	Alive without relapse ∼1.5 y after AHCT
21	0.6	46	2	ALK-ve ALCL	CHOEP ×3 – BV ×8 – CR1	CR1	CR	Alive without relapse ∼1.5 y after AHCT
22	0.6	32	1	ALK-ve ALCL	A + CHP ×6	CR1	CR	Alive without relapse ∼7 mos after AHCT

Alk-ve ALCL, Anaplastic large cell lymphoma; Gem/Ox, gemcitabine and oxaliplatin; HSTCL, hepatosplenic T-cell lymphoma; MEITL, monomorphic epithelial intestinal T-cell lymphoma; UPN- unidentified patient number.

View Large

This Feature Is Available To Subscribers Only